Eli Lilly Stock (LLY) Has 45% Upside, Says Citigroup
Citigroup analyst Geoff Meacham raised Eli Lilly's (LLY) price target to $1,600, the highest on Wall Street, citing a 45% upside. Meacham highlighted LLY's 60% market share in weight-loss drugs and $14.9B quarterly sales. LLY's stock has dropped 8% in a month, presenting a buying opportunity, according to the analyst. Novo Nordisk (NVO) is rebranding to 'Novo' and plans to outline further changes on Sept. 21.
How this was made
The 30-second read
Why it matters
Analyst’s aggressive target could prompt short‑term buying pressure, but the view hinges on continued dominance in weight‑loss drugs.
Market read
A fresh, high price target for a large‑cap pharma stock may influence investor sentiment and sector positioning.
What to watch
Potential regulatory or safety concerns for new obesity drugs could temper upside.
Background
The article reports a new Citigroup price target and reiterates a Buy rating for Eli Lilly (LLY).
Ticker impact
Citigroup analyst Geoff Meacham raises price target to $1,600, a 45% upside, and reiterates Buy rating.
Potential short-term upside of 5‑10% as investors adjust expectations.
The target is substantially above current price and reflects a bullish view on weight‑loss drug market share.
Market effects
May lift sentiment for the broader pharma/obesity‑drug sector.
U.S. biotech and large‑cap pharma stocks could see modest gains.
Weight‑loss drug market dynamics are global; rivals may be re‑priced.
Counterpoint
Target may be overly optimistic given competitive pressure from Novo Nordisk.
Key entities
- companyEli Lilly
Pharmaceutical company with leading weight‑loss drug portfolio.
- financial_institutionCitigroup
Brokerage firm providing the analyst rating.
